European Medicines Agency recommends approval of “Xevudy” and “Kineret” for the treatment of Covid-19


The European Medicines Agency (EMA) has announced that it is recommending the approval of two new therapies for COVID-19, Xevudy (sotrovimab) and Kineret (anakinra).

“Xevudy” (sotrovimab) is a monoclonal antibody medicine intended for the treatment of COVID-19 in adults and adolescents (from 12 years of age and weighing at least 40 kg) who do not need supplemental oxygen and are at increased risk of developing severe disease.

Xevudy is the third monoclonal antibody treatment recommended in the EU for the treatment of COVID-19 and follows the approval of Regkirona and Ronapreve in November. Monoclonal antibodies are proteins designed to attach to a specific target, in this case the SARS-CoV-2 spike protein (the virus that causes COVID-19), which the virus uses to enter human cells.

Kineret (anakinra) is an immunosuppressive drug already approved in the EU for the treatment of various inflammatory conditions. Its indication has now been extended to include COVID-19 treatment in adult patients with pneumonia who need supplemental oxygen (low or high flow oxygen) and who are at risk of developing severe respiratory failure.

In patients with COVID-19, the drug is thought to reduce the inflammation associated with COVID-19 and thus reduce damage to the lower airways, preventing the development of severe respiratory failure.

Source: ΑΠΕ-ΜΠΕ  

Leave A Reply

Your email address will not be published.